Trial Profile
A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic Veno-occlusive Disease (VOD) Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Defibrotide (Primary)
- Indications Hepatic veno-occlusive disease; Veno-occlusive disorders
- Focus Adverse reactions
- Acronyms EBMT PASS
- Sponsors Jazz Pharmaceuticals Inc
- 12 Dec 2023 Results of pooled analysis (DEFIFrance and EBMT PASS ), analysing the treatment duration and time to resolution of Veno-occlusive disease/sinusoidal obstruction syndrome in patients given defibrotide for the treatment of severe or nonsevere Veno-occlusive disease/sinusoidal obstruction syndrome post-hematopoietic cell transplantation, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 13 Dec 2022 Results of a pooled analysis from two clinical registries: DEFIFrance and EBMT PASS assessing time to diagnosis, treatment initiation and duration, and resolution of VOD/SOS in patients given defibrotide for treatment of severe or non-severe VOD/SOS post-HCT presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 03 Nov 2022 According to a Jazz Pharmaceutical media release, pooled analysis of two registry studies (DEFIFrance and EBMT PASS) will be presented at the American Society of Hematology (ASH) Annual Meeting.